Archives for March 2016

Army: (MRPRA): Military Risk Factors Research Award

notice

Abstract
The intent of the FY15 Military Risk Factors Research Award (MRFA) is to facilitate high-impact, systematic, population-based research investigating the association between TBI and the subsequent development of AD.Applications should describe how the association of TBI and subsequent AD will be characterized. Applications should also describe how the proposed study will work with well-defined, already identified study cohorts. Applications should carefully consider how their studies will characterize the cognitive and behavioral symptoms that result in functional impairments in the proposed cohort. Studies that use combinations of measures (e.g., neuropsychological assessments, imaging, genomics, and cerebral spinal fluid) are encouraged. Applications that develop interdisciplinary teams or consortia as part of the support plan for executing the research are encouraged.

Applications must detail and demonstrate expedited access to a well-defined, already identified study cohort. Preliminary data that supports how the cohort will be used in the study is also required. The preliminary data must strongly support the proposed research hypothesis (or hypotheses).

Army: (MRPRA): Quality of Life Research Award

see notice

Abstract
The intent of the research funded through the FY15 Quality of Life Research Award (QUAL) is to reduce the burden on caregivers and individuals affected by the common symptoms of both TBI and AD, especially in themilitary community.

Overarching Challenges: This QUAL funding opportunity requires applications to address one or both of the following PRARP Overarching Challenges:
– Quality of Life: The need for technologies, tests, interventions, epidemiological studies, or devices with the potential to benefit individuals suffering from common symptoms of TBI and AD.
– Caregiver Burden: The need for technologies, tests, interventions, epidemiological studies, or devices with the potential to reduce caregiver burden for individuals affected by the common symptoms of TBI and AD.

In addition to addressing one or both of the specified Overarching Challenges, applications must also address at least one of the following FY14 PRARP Focus Areas in support of the specified Overarching Challenge(s). An application that proposes research outside of these Focus Areas is acceptable, as long as the applicant provides a strong rationale:
– Care Interventions and Quality of Life: Research intended to stabilize or improve the quality of life of those affected by the common symptoms of TBIand AD. Examples of research in this focus area include:
– Cognitive Training Interventions
– Studies of Health and Wellness
– Behavioral Interventions
– Neuropsychological Interventions

Caregiver support: Research intended to reduce the burden of care on the caregiver for individuals affected by the common symptoms of TBI and AD. Examples of research in this focus area include:
– Caregiver Training
– Home Based Support
– Behavioral Interventions
– Relationship Interventions

While the QUAL mechanism can be used to support clinical research, the following is specifically discouraged under the FY14 PRARP:
– Pharmacologic Interventions: Clinical or Basic research requiring investigational or FDA-approved drugs or medicines.
– Drug Discovery and Development: Clinical or Basic research directly leading to the development of investigational medicines, drugs or agents.

Army: Peer Reviewed Alzheimer’s Disease Research Program: Convergence Science Research Award

notice

The PRARP (formerly the Militarily Relevant Peer Reviewed Alzheimer’s Disease Research Program) was initiated in 2011 to address the long-term consequences of traumatic brain injury (TBI) as they pertain to Alzheimer’sdisease (AD). Military personnel and other individuals who suffer from TBI face an increased risk for developing several long-term health problems. These conditions include Alzheimer’s-like dementia, aggression, memory loss, depression, and symptoms similar to those of other neurological diseases. The PRARP is devoted to (1) understanding the association between TBI and AD; and (2) reducing the burden on affected individuals and caregivers, especially in the military and Veteran communities. Support for these objectives is anticipated to be delivered by the research community through a combination of mechanistic and preclinical studies.

Army: Traumatic Brain Injury Endpoints Development

notice

As of 2015, no drug has been approved by the US Food and Drug Administration (FDA) to treat traumatic brain injury (TBI). Decades of well-designed clinical trials have failed. The TED Initiative, funded by theDepartment of Defense, with support from a robust private-public partnership, is a 5-year direct collaboration between leading academic clinician-scientists, the FDA, industry leaders in biotechnology and imaging technology, philanthropies, and patient advocacy groups. Our ultimate goal is to advance the design of clinical trials that will lead to the first successful treatments of acute TBI.

Through early and iterative collaboration with FDA, TED’s overarching aims are to provide the field with a set of validated tools for TBI research; to precisely diagnose this multi-dimensional condition, to accurately stratify patients into trials based on characteristics of their injury, reliably measure the effects of injury over time, and to confirm that experimental drugs and devices are engaging their molecular target at the dose and schedule tested. Such tools will overcome the inherent limitations of the long-used symptom-based TBIclassification approaches that divide patients into crude categories of mild, moderate, and severe, using the Glasgow Coma Scale (GCS); outcomes have traditionally been measured using the equally rudimentary Glasgow Outcome Scale-Extended (GOS-E). These measures do not permit mechanistic targeting for clinical trials or detection of differential effectiveness among TBI phenotypes. The GOS-E and GCS, along with head CT, are currently the only FDA-accepted tools for stratifying patients into TBI clinical trials and measuring outcomes.

The Seed Projects are designed to encourage investigators to identify and work toward validation of TBI COAs, blood-based biomarkers, and neuroimaging biomarkers using novel and traditional methodologies that will be presented to the FDA as validated endpoints and outcomes. These endpoints should support enrichment of patient selection/stratification for TBI clinical trials, and/or may serve as treatment endpoints. Seed projects must address the goals and bridge research gaps identified by the TED Steering Committee and its Government Steering Committee (GSC) . Seed Projects, in most cases, will focus on integrated and systematic analysis of the TED Metadataset for either: (i) existing clinical or imaging data, and/or (ii) collection of new data from existing biosamples. Applicants are encouraged to collaborate with private industry partners to leverage resources.

Projects should address one or more of the following goals:

A. Research to support TBI clinical outcome assessment tools that are suitable for use in clinical trials. Currently, almost all severe TBI therapeutic trials use incidents of adverse events (e.g., mortality) as a short-term outcome measure; the GOS, GOS-E, and Disability Rating Scale (DRS) are employed as long-term (3-6 month) primary endpoints for assessing drug efficacy. Most of these tools were developed for more severe forms of TBI, thus they may not be sufficiently sensitive to detect the diverse neurobehavioral deficits that can result from mild/moderate TBI. Validation of additional COAs could help enhance and improve these aspects of TBI clinical trials.

B. Research to support the use of TBI diagnostic biomarkers (blood-based and imaging) for patient stratification that are acceptable for use in therapeutic trials submitted to the FDA; to enrich for TBI populations that might be most responsive to treatment, to ultimately enhance and improve TBI therapeutic trials.

C. Research to support the use of TBI predictive biomarkers for patient stratification that are acceptable for use in therapeutic trials submitted to the FDA; to enrich for TBI patients that are likely to develop persistent post-concussive symptoms, to ultimately enhance and improve TBI therapeutic trials.

D. Research to support the use of pharmacodynamic biomarkers that are acceptable for use in therapeutic trials submitted to the FDA; to track whether therapeutic agents are effectively reaching their targets and exerting beneficial effects. The use of a TBI pharmacodynamic biomarker in conjunction with primary outcome data could provide more detailed insights as to why clinical efficacy is not demonstrated in subsets of subjects and help shed light on future improvements of drug trials of the same or related compounds.

Sarchet Seminar Series – April 5

April 5 2016

2 – 3:15 pm

213 Butler-Carlton Civil Engineering Hall

article by Peter Ehrhard

Florida State researcher guest lecture

Friday March 25

4 PM

Room G-5 Rolla Building

Dr. Nan Jiang, postdoctoral associate researcher of scientific computing at Florida State University, will present a guest lecture titled “New Algorithms and Models for Computing Fluid Flow Equations” at 4 p.m. Friday, March 25, in Room G-5 Rolla Building. Jiang will present several new results in developing efficient and effective numerical methods for computing fluid flow equations. from article by Peter Ehrhard

@MU: Plant Symposium

Registration: http://ipg.missouri.edu/symposium/

2016SymposiumPosterFinal

Innovation and Entrepreneurship Session

spring 2016 info mtg flyer eship

Presentation: Want to be an Entrepreneur?

Dear Colleagues and Students,

Dr. Delbert Day, Curators’ Professor Emeritus of Materials Science and Engineering at S&T, will be delivering his hallmark Engineering Entrepreneurship Presentation in class as follows:

Presenter: Dr. Delbert Day

Seminar: Want to be an Entrepreneur?

Time & Date: 12:30 p.m., Thursday, March 24, 2016

Place: Room 199 Toomey Hall

Do come out to hear and support his very enthusiastic and inspiring talk.

With best regards,

Ashok Midha

NIST: Smart Grid Interoperability Standards Cooperative Agreement Program

notice

Abstract
NIST invites applications from eligible applicants for a program with substantial NIST participation that will support continuous innovation of the electrical grid through the coordination and acceleration of standards development and harmonization and advancement of the interoperability and security of smart grid devices and systems. The applicant will work with NIST in its fulfillment of standards coordination activities as mandated under the Energy Independence and Security Act of 2007 (EISA).